These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17298479)

  • 1. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.
    Dickinson GL; Lennard MS; Tucker GT; Rostami-Hodjegan A
    Br J Clin Pharmacol; 2007 Jul; 64(1):14-26. PubMed ID: 17298479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.
    Moridani M; Fu L; Selby R; Yun F; Sukovic T; Wong B; Cole DE
    Clin Biochem; 2006 Jun; 39(6):606-12. PubMed ID: 16630605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
    Siddiqi A; Khan DA; Khan FA; Naveed AK
    Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation].
    Sychev DA; Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG
    Klin Med (Mosk); 2007; 85(1):57-60. PubMed ID: 17419358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
    Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
    Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.
    Yildirim H; Tamer L; Sucu N; Atik U
    Med Princ Pract; 2008; 17(6):464-7. PubMed ID: 18836275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Warfarin in the treatment of antiphospholipid syndrome].
    Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
    Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.
    Muszkat M; Bialer O; Blotnick S; Adar L; Xie HG; Ufer M; Cascorbi I; Caraco Y
    Clin Ther; 2010 Feb; 32(2):347-56. PubMed ID: 20206792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
    Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V
    Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype.
    Dericioglu N; Babaoglu MO; Saygi S; Bozkurt A; Yasar U
    Ann Pharmacother; 2004 May; 38(5):899. PubMed ID: 15039471
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
    Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.
    Xue L; Holford N; Ding XL; Shen ZY; Huang CR; Zhang H; Zhang JJ; Guo ZN; Xie C; Zhou L; Chen ZY; Liu LS; Miao LY
    Br J Clin Pharmacol; 2017 Apr; 83(4):823-835. PubMed ID: 27763679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
    McMillin GA; Melis R; Wilson A; Strong MB; Wanner NA; Vinik RG; Peters CL; Pendleton RC
    Ther Drug Monit; 2010 Jun; 32(3):338-45. PubMed ID: 20386359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype.
    Kwon MJ; On YK; Huh W; Ko JW; Kim DK; Kim JS; Lee SY
    Clin Chim Acta; 2011 Nov; 412(23-24):2343-5. PubMed ID: 21782804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.
    Ruud E; Holmstrøm H; Bergan S; Wesenberg F
    Pediatr Blood Cancer; 2008 Mar; 50(3):710-3. PubMed ID: 17226852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.
    Ma JD; Nafziger AN; Kashuba AD; Kim MJ; Gaedigk A; Rowland E; Kim JS; Bertino JS
    J Clin Pharmacol; 2004 Jun; 44(6):570-6. PubMed ID: 15145963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various
    Cheng S; Flora DR; Rettie AE; Brundage RC; Tracy TS
    Drug Metab Dispos; 2023 Feb; 51(2):257-267. PubMed ID: 36379708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9.
    Klein K; Gueorguieva I; Aarons L
    J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):147-60. PubMed ID: 22270321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.